Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM5 | Q9NZQ8 | 4/20 | 1.00 |
| ▸ | POLB | P06746 | 4/20 | 0.61 |
| ▸ | MAPT | P10636 | 3/20 | 0.61 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | PKM | P14618 | 1/20 | 0.57 |
| ▸ | APEX1 | P27695 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31612234 | 1.00 | TRPM5 (1.00) | TRPM5POLBMAPTHPGDALDH1A1 | |
| SCHEMBL3861198 | 1.00 | TRPM5 (1.00) | TRPM5POLBMAPTHPGDALDH1A1 | |
| SCHEMBL3500356 | 0.82 | MAPT (0.75) | TRPM5POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL3500390 | 0.82 | MAPT (0.75) | TRPM5POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL28811925 | 0.81 | TRPM5 (0.69) | TRPM5MAPTALDH1A1GAACYP3A4 | |
| SCHEMBL7977521 | 0.79 | KDM4E (0.75) | TRPM5POLBMAPTHPGDALDH1A1 | |
| SCHEMBL12793829 | 0.77 | ALDH1A1 (0.66) | TRPM5POLBMAPTHPGDALDH1A1 | |
| SCHEMBL13056426 | 0.77 | TRPM5 (0.62) | TRPM5POLBMAPTHPGDALDH1A1 | |
| SCHEMBL3633028 | 0.76 | TRPM5 (0.62) | TRPM5POLBMAPTGAASMN1; SMN2 | |
| SCHEMBL3633031 | 0.76 | TRPM5 (0.62) | TRPM5POLBMAPTGAASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | claimed |
| EP-2107908-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | Redpoint Bio Corporation (US) | 2009-10-14 | — | — | EP | claimed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | claimed |
| WO-2008097504-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | REDPOINT BIO CORPORATION (US) | 2008-08-14 | — | — | WO | claimed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | claimed |
| US-8193168-B2 | Use of a TRPM5 inhibitor to regulate insulin and GLP-1 release | REDPOINT BIO CORPORATION (US) | 2012-06-05 | — | — | US | disclosed |
| EP-2107908-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | Redpoint Bio Corporation (US) | 2009-10-14 | — | — | EP | disclosed |
| EP-1951215-A4 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORP (US) | 2009-07-29 | — | — | EP | disclosed |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | REDPOINT BIO CORPORATION (US) | 2008-12-11 | — | — | US | disclosed |
| WO-2008097504-A2 | USE OF A TRPM5 INHIBITOR TO REGULATE INSULIN AND GLP-1 RELEASE | REDPOINT BIO CORPORATION (US) | 2008-08-14 | — | — | WO | disclosed |
| EP-1951215-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | Redpoint Bio Corporation (US) | 2008-08-06 | — | — | EP | disclosed |
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | LINQUAGEN CORP. | 2007-09-06 | — | — | US | disclosed |
| WO-2007056159-A2 | HYDRAZONE DERIVATIVES AND USES THEREOF | REDPOINT BIO CORPORATION (US) | 2007-05-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207093-A1 | Hydrazone derivatives and uses thereof | TAS2R1, TAS2R5, TAS1R1 | TRPM5 49/4885POLB 4551/4885MAPT 4421/4885 |
| US-20080306030-A1 | Use of a TRPM5 Inhibitor to Regulate Insulin and GLP-1 Release | GLP1R, GIPR, TRPM5 | TRPM5 3/4885POLB 4849/4885MAPT 4601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.